Asset sale Announced

GSK acquisition of trispecific T cell-engager (TCE) asset

US$750m consideration

Announced Sep 2026

Advisers

trispecific T cell-engager (TCE) asset

Target

GSK

Acquirer

Legal adviser
Target
trispecific T cell-engager (TCE) asset
Acquirer
GSK
Seller
Chimagen Biosciences
Target based in
China (unverified)
Buyer based in
United Kingdom
Seller based in
China (unverified)
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.